Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage

Stroke (HP Adams, Section Editor)
  • 576 Downloads
Part of the following topical collections:
  1. Topical Collection on Stroke

Abstract

Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.

Keywords

Anticoagulants Apixaban Dabigatran Intracerebral hemorrhage Target-specific oral anticoagulants Prothrombin complex concentrate Rivaroxaban Vitamin K Warfarin 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Magee G, Peters C, Zbrozek A. Analysis of inpatient use of fresh frozen plasma and other therapies and associated outcomes in patients with major bleeds from vitamin K antagonism. Clin Ther. 2013;35:1432–43. Elsevier.PubMedCrossRefGoogle Scholar
  3. 3.
    Freedman JE, Gersh BJ. Atrial fibrillation and stroke prevention in aging patients: what’s good can be even better. Circulation. 2014;130:129–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Veltkamp R, Rizos T, Horstmann S. Intracerebral bleeding in patients on antithrombotic agents. Semin Thromb Hemost. 2013;39:963–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Virjo I, Mäkelä K, Aho J, Kalliola P, Kurunmäki H, Uusitalo L, et al. Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland. Scand J Prim Health Care. 2010;28:237–41.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76:1238–44.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Towfighi A, Greenberg SM, Rosand J. Treatment and prevention of primary intracerebral hemorrhage. Semin Neurol. 2005;25:445–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Bechtel BF, Nunez TC, Lyon JA, Cotton BA, Barrett TW. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med. 2011;4:40. Springer Open Ltd.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Flaherty M, Tao H, Haverbusch M. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71:1084–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373:1632–44. Elsevier Ltd.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Schaefer JH, Leung W, Wu L, Van Cott EM, Lok J, Whalen M, et al. Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. J Cereb Blood Flow Metab. 2014;34:870–5. Nature Publishing Group.PubMedCrossRefGoogle Scholar
  14. 14.•
    Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e152S–84. The most recent guidelines from the American College of Chest Physicians summarizing recommendations for the management of antithrombotic therapy.Google Scholar
  15. 15.
    Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745–52.PubMedCrossRefGoogle Scholar
  16. 16.••
    Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43. A randomized multicenter trial investigating the safety and efficacy of 4F-PCC for patients with warfarin-associated coagulopathy. Trial results led to the approval of 4F-PCC in the United States for urgent warfarin reversal.PubMedGoogle Scholar
  17. 17.
    Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37:256–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest J. 2001;119:8S–21. American College of Chest Physicians.CrossRefGoogle Scholar
  19. 19.•
    Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–90. A meta-analysis of randomized clinical trials evaluating the incidence of intracranial hemorrhage in patients receiving warfarin and TSOAs.PubMedGoogle Scholar
  20. 20.
    Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep. 2014;16:480.PubMedCrossRefGoogle Scholar
  21. 21.•
    Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24–33. This article provides an overview of TSOAs and their pharmacologic characteristics.PubMedCrossRefGoogle Scholar
  22. 22.
    Suryanarayan D, Schulman S. Potential antidotes for reversal of old and new oral anticoagulants. Thromb Res. 2014;133(Suppl):S158–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Weitz DS, Weitz JI. Update on heparin: what do we need to know? J Thromb Thrombolysis. 2010;29:199–207.PubMedCrossRefGoogle Scholar
  24. 24.
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy heparin and low-molecular-weight heparin. Chest. 2004;126:188S–203.PubMedCrossRefGoogle Scholar
  25. 25.
    Sarode R, Rawal A, Lee R, Shen Y-M, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol. 2006;132:604–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493–502.PubMedCrossRefGoogle Scholar
  27. 27.•
    Kitchen S, Gray E, Mackie I, Baglin T, Makris M, committee the B. Measurement of non-Coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014;166:830–41. The most recent guidelines from the British Committee for Standards in Haematology characterizing appropriate tests for evaluating the effects of non-Coumarin anticoagulants.PubMedCrossRefGoogle Scholar
  28. 28.
    Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost. 2013;11:122–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675–86.PubMedCrossRefGoogle Scholar
  30. 30.•
    Bowry R, Fraser S, Archeval-Lao JM, Parker SA, Cai C, Rahbar MH, et al. Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke. 2014;45:880–3. This article characterizes the use of thrombelastography to detect the anticoagulant effects of rivaroxaban in patients presenting with ischemic stroke.PubMedCrossRefGoogle Scholar
  31. 31.•
    Adelmann D, Marion W, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res. 2014;134(4):918–23. This article characterizes the use of rotational thrombelastography for detecting anticoagulant effects in patients receiving varying doses of either rivaroxaban or apixaban. PubMedCrossRefGoogle Scholar
  32. 32.
    Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O’malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166:391–7.PubMedGoogle Scholar
  33. 33.
    Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115:145–9.PubMedCrossRefGoogle Scholar
  34. 34.••
    Tazarourte K, Riou B, Tremey B, Samama C-M, Vicaut E, Vigué B. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Crit Care. 2014;18:R81. A prospective observational study of patients presenting with vitamin K-antagonist-associated severe bleeding, demonstrating that administration of vitamin K and PCC within 8 h of presentation resulted in a threefold decrease in the 7-day mortality of ICH.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37:151–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion. 2011;51:338–43.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52 Suppl 1:65S–79.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care. 2010;12:403–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol. 2011;154:311–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013;198:1–7.Google Scholar
  41. 41.
    Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17:R76. BioMed Central Ltd.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594–9.PubMedCrossRefGoogle Scholar
  43. 43.••
    Zhou W, Zorn M, Nawroth P, Bütehorn U, Perzborn E, Heitmeier S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44:771–8. This article characterizes an experimental mouse model of rivaroxaban-associated cerebral hemorrhage and the effects of various hemostatic agents on intracerebral hematoma expansion.PubMedCrossRefGoogle Scholar
  44. 44.
    Van Ryn J, Stangier J, Haertter S, Liesenfeld K-H, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116.PubMedCrossRefGoogle Scholar
  45. 45.
    Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49:259–68.PubMedCrossRefGoogle Scholar
  46. 46.•
    Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost. 2014;111:189–98. This article provides a comprehensive review of data regarding the use of PCC for reversing the anticoagulant effects of TSOAs.PubMedCrossRefGoogle Scholar
  47. 47.
    Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98:790–7.PubMedGoogle Scholar
  48. 48.
    Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141–5. Wiley Subscription Services, Inc., A Wiley Company.PubMedCrossRefGoogle Scholar
  49. 49.
    Lazo-Langner A, Lang E, Douketis J. Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care. 2013;17:230.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Díaz MQ, Borobia AM, Núñez MAR, Virto AMM, Fabra S, Casado MS, et al. Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency department. Haematologica. 2013;98:e143–4.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost. 2013;110:162–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Faust AC, Peterson EJ. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report. J Emerg Med. 2014. doi:10.1016/j.jemermed.2013.11.097.PubMedGoogle Scholar
  53. 53.••
    Schiele F, Van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62. This article characterizes the first specific antidote for dabigatran, aDabi-Fab, demonstrating reversal of the anticoagulant effects in human plasma in vitro and in rats in vivo.PubMedCrossRefGoogle Scholar
  54. 54.••
    Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51. This article characterizes the study of a specific antidote for factor Xa inhibitors, andexanet alfa, demonstrating its ability to reverse the anticoagulant effects of both fondaparinux and enoxaparin.PubMedCrossRefGoogle Scholar
  55. 55.
    Carr JA, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino). 1999;40:659–66.Google Scholar
  56. 56.
    Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160:35–46.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Transfusion Medicine and Hemostasis, Department of PathologyUT Southwestern Medical CenterDallasUSA

Personalised recommendations